ADCT Fundamental Analysis - ADC THERAPEUTICS SA

Name: ADC THERAPEUTICS SA (ADCT) Stock
Brand: ADC THERAPEUTICS SA
Rating: 6 (3 reviews)

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to ADCT. ADCT was compared to 533 industry peers in the Biotechnology industry. Both the profitability and financial health of ADCT have multiple concerns. While showing a medium growth rate, ADCT is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

ADCT had negative earnings in the past year.

In the past year ADCT has reported a negative cash flow from operations.

In the past 5 years ADCT always reported negative net income.

In the past 5 years ADCT always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -57.61%, ADCT is in line with its industry, outperforming 44.09% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-57.61%
ROE	N/A
ROIC	N/A

ROA(3y)-48.71%

ROA(5y)-46.26%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 92.73%, ADCT belongs to the top of the industry, outperforming 92.87% of the companies in the same industry.

In the last couple of years the Gross Margin of ADCT has declined.

The Profit Margin and Operating Margin are not available for ADCT so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	92.73%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.51%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ADCT does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, ADCT has more shares outstanding

The number of shares outstanding for ADCT has been increased compared to 5 years ago.

Compared to 1 year ago, ADCT has a worse debt to assets ratio.

2.2 Solvency

ADCT has an Altman-Z score of -7.52. This is a bad value and indicates that ADCT is not financially healthy and even has some risk of bankruptcy.

ADCT has a Altman-Z score of -7.52. This is in the lower half of the industry: ADCT underperforms 67.54% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-7.52

ROIC/WACCN/A

WACC4.71%

2.3 Liquidity

ADCT has a Current Ratio of 4.63. This indicates that ADCT is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 4.63, ADCT is in line with its industry, outperforming 52.72% of the companies in the same industry.

A Quick Ratio of 4.34 indicates that ADCT has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 4.34, ADCT is in line with its industry, outperforming 51.97% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	4.63
Quick Ratio	4.34

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ADCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.35%, which is quite impressive.

The Revenue for ADCT has decreased by -39.09% in the past year. This is quite bad

ADCT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 98.48% yearly.

EPS 1Y (TTM)44.35%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%28.57%

Revenue 1Y (TTM)-39.09%

Revenue growth 3Y27.85%

Revenue growth 5Y98.48%

Sales Q2Q%-11.03%

3.2 Future

Based on estimates for the next years, ADCT will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.54% on average per year.

Based on estimates for the next years, ADCT will show a very strong growth in Revenue. The Revenue will grow by 33.94% on average per year.

EPS Next Y5.73%

EPS Next 2Y9.1%

EPS Next 3Y13.54%

EPS Next 5YN/A

Revenue Next Year6.62%

Revenue Next 2Y5.72%

Revenue Next 3Y27.81%

Revenue Next 5Y33.94%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ADCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADCT. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ADCT's earnings are expected to grow with 13.54% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y9.1%

EPS Next 3Y13.54%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ADCT does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ADC THERAPEUTICS SA

NYSE:ADCT (11/25/2025, 8:24:05 PM)

After market: 4.39 0 (0%)

4.39

+0.02 (+0.46%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-10 2025-11-10/bmo

Earnings (Next)03-25 2026-03-25/amc

Inst Owners59.3%

Inst Owner Change-0.59%

Ins Owners5.81%

Ins Owner Change0.82%

Market Cap493.87M

Revenue(TTM)75.21M

Net Income(TTM)-166.94M

Analysts86.67

Price Target8.16 (85.88%)

Short Float %7.27%

Short Ratio6.99

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)20.04%

Min EPS beat(2)18.68%

Max EPS beat(2)21.4%

EPS beat(4)4

Avg EPS beat(4)20.88%

Min EPS beat(4)12.49%

Max EPS beat(4)30.94%

EPS beat(8)6

Avg EPS beat(8)-0.22%

EPS beat(12)7

Avg EPS beat(12)-2.22%

EPS beat(16)10

Avg EPS beat(16)1.26%

Revenue beat(2)1

Avg Revenue beat(2)-1.14%

Min Revenue beat(2)-5.69%

Max Revenue beat(2)3.41%

Revenue beat(4)2

Avg Revenue beat(4)3.11%

Min Revenue beat(4)-12.78%

Max Revenue beat(4)27.51%

Revenue beat(8)3

Avg Revenue beat(8)0.81%

Revenue beat(12)4

Avg Revenue beat(12)-4.76%

Revenue beat(16)7

Avg Revenue beat(16)2.72%

PT rev (1m)-3.03%

PT rev (3m)-3.03%

EPS NQ rev (1m)8.42%

EPS NQ rev (3m)7.13%

EPS NY rev (1m)0%

EPS NY rev (3m)-1.13%

Revenue NQ rev (1m)-1.91%

Revenue NQ rev (3m)0.37%

Revenue NY rev (1m)0%

Revenue NY rev (3m)-0.82%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	6.57
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-1.33

EYN/A

EPS(NY)-1.34

Fwd EYN/A

FCF(TTM)-1.18

FCFYN/A

OCF(TTM)-1.17

OCFYN/A

SpS0.67

BVpS-2.12

TBVpS-2.12

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-57.61%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	92.73%
FCFM	N/A

ROA(3y)-48.71%

ROA(5y)-46.26%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.51%

GM growth 5YN/A

F-Score2

Asset Turnover0.26

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	-79.73%
Cap/Sales	0.47%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	4.63
Quick Ratio	4.34
Altman-Z	-7.52

F-Score2

WACC4.71%

ROIC/WACCN/A

Cap/Depr(3y)144.88%

Cap/Depr(5y)161.59%

Cap/Sales(3y)2.31%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)44.35%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%28.57%

EPS Next Y5.73%

EPS Next 2Y9.1%

EPS Next 3Y13.54%

EPS Next 5YN/A

Revenue 1Y (TTM)-39.09%

Revenue growth 3Y27.85%

Revenue growth 5Y98.48%

Sales Q2Q%-11.03%

Revenue Next Year6.62%

Revenue Next 2Y5.72%

Revenue Next 3Y27.81%

Revenue Next 5Y33.94%

EBIT growth 1Y53.62%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-21.15%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y6.01%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y4.21%

OCF growth 3YN/A

OCF growth 5YN/A

ADC THERAPEUTICS SA / ADCT FAQ

Can you provide the ChartMill fundamental rating for ADC THERAPEUTICS SA?

ChartMill assigns a fundamental rating of 2 / 10 to ADCT.

What is the valuation status for ADCT stock?

ChartMill assigns a valuation rating of 0 / 10 to ADC THERAPEUTICS SA (ADCT). This can be considered as Overvalued.

Can you provide the profitability details for ADC THERAPEUTICS SA?

ADC THERAPEUTICS SA (ADCT) has a profitability rating of 1 / 10.

What is the financial health of ADC THERAPEUTICS SA (ADCT) stock?

The financial health rating of ADC THERAPEUTICS SA (ADCT) is 2 / 10.

ADC THERAPEUTICS SA (ADCT) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

ADC THERAPEUTICS SA / ADCT FAQ

Can you provide the ChartMill fundamental rating for ADC THERAPEUTICS SA?

What is the valuation status for ADCT stock?

Can you provide the profitability details for ADC THERAPEUTICS SA?

What is the financial health of ADC THERAPEUTICS SA (ADCT) stock?